Drug intelligence / Profile preview

MIC6701

Development stage: Preclinical
Lead developer: Micar Innovation
Modality: Small Molecules

Overview

MIC6701 is a preclinical-stage small molecule therapeutic being developed by Micar Innovation (also known as Micar21) for the treatment of colorectal cancer. Micar Innovation utilizes a proprietary computational drug discovery platform to identify and optimize first-in-class small molecules. As of the current pipeline status, MIC6701 is in the early stages of development, and its specific biological target remains undisclosed by the company. The drug is part of a broader oncology portfolio aimed at addressing unmet medical needs through structure-based drug design and in silico screening.

Beyond the preview

Go deeper on MIC6701.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on MIC6701.

Explore the full profile